# A Clinical Trial on Autologous NK Cells Combined With GD2 Monoclonal Antibody in the Treatment of Children With Newly Diagnosed High-risk or Relapsed/Refractory Neuroblastoma

> **NCT06948994** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Guangzhou Women and Children's Medical Center** · enrollment: 15 (estimated)

## Conditions studied

- Neuroblastoma
- GD2 Antibody
- Autologous NK Cell

## Interventions

- **COMBINATION_PRODUCT:** autologous NK cell plus GD2 antibody

## Key facts

- **NCT ID:** NCT06948994
- **Lead sponsor:** Guangzhou Women and Children's Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-05-01
- **Primary completion:** 2027-04-30
- **Final completion:** 2028-04-30
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2025-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06948994

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06948994, "A Clinical Trial on Autologous NK Cells Combined With GD2 Monoclonal Antibody in the Treatment of Children With Newly Diagnosed High-risk or Relapsed/Refractory Neuroblastoma". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06948994. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*